Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LH
Strong BuyPremium GrowerFLAGLabcorp Holdings Inc. · Healthcare · United States · $27.2B · Avg Vol: $203M/d
Labcorp clears stage one with all legs above the floor and a buyback retiring 0.49% of shares. Insiders sold 0.01% with no offsetting purchases, so on a strict reading there is net selling and stage two blocks approval.
COMPANY DESCRIPTION
Labcorp Holdings Inc. is a leading global life sciences company providing comprehensive clinical laboratory services and drug development solutions. Its extensive network of laboratories, broad test menu, and significant scale create efficiencies and brand loyalty. Labcorp is a dual-focused healthcare giant, operating as both a major clinical diagnostic provider and a contract research organization.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.9B | 12.2B | 13.0B | 14.0B | 5.6% | 14.3B | 14.7B | 15.5B | 5.3% |
| EPS | 14.05 | 4.80 | 8.89 | 10.54 | -9.1% | 12.10 | 11.76 | 12.72 | 9.9% |
| Shares | 88.2M | 83.9M | 83.4M | 82.2M | -6.8% | 81.1M | — | — | — |
| Debt | 6.2B | 6.0B | 7.3B | 6.5B | 1.5% | 6.8B | — | — | — |
| Equity | 10.1B | 7.9B | 8.1B | 8.6B | -5.1% | — | — | — | — |
| Op CF | 2.0B | 1.3B | 1.6B | 1.6B | -5.7% | 1.6B | — | — | — |
| Inv CF | -1.7B | -1.2B | -1.4B | -1.2B | — | — | — | — | — |
| Fin CF | -1.3B | -59.3M | 779.9M | -1.5B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LH | Labcorp Holdings Inc.(you) | $27.2B | 83 | Strong Buy |
| DGX | Quest Diagnostics Incorporated | $26.8B | 82 | Strong Buy |
| ILMN | Illumina, Inc. | $32.6B | 75 | Buy |
| MEDP | Medpace Holdings, Inc. | $16.8B | 80 | Strong Buy |
| A | Agilent Technologies, Inc. | $43.4B | 75 | Buy |
| IQV | IQVIA Holdings Inc. | $43.1B | 73 | Buy |
| WAT | Waters Corporation | $40.7B | 62 | Hold |
| RVTY | Revvity, Inc. | $14.4B | 64 | Hold |
| CRL | Charles River Laboratories International, Inc. | $14.0B | 63 | Hold |
| SHC | Sotera Health Company | $5.5B | 81 | Strong Buy |
Peer medians: ROE -30.7% · P/E 26.9x · Gross margin 58.3%